Cover Image
市場調查報告書

EpiCast Report:急性骨髓性白血病 (AML) - 至2024年的流行病學預測

EpiCast Report: Acute Myeloid Leukemia - Epidemiology Forecast to 2024

出版商 GlobalData 商品編碼 274254
出版日期 內容資訊 英文 74 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:急性骨髓性白血病 (AML) - 至2024年的流行病學預測 EpiCast Report: Acute Myeloid Leukemia - Epidemiology Forecast to 2024
出版日期: 2015年10月08日 內容資訊: 英文 74 Pages
簡介

急性骨髓性白血病 (AML) ,也叫骨髓性白血病 (ML) 或急性非淋巴性白血病 (ANLL) 。全球主要7個國家 (美國、法國、德國、義大利、西班牙、英國、日本)確診為急性骨髓性白血病 (AML) 的患者數,預計從2014年的40,661人,今後10年達到48,918人,1年各增加2.03%。

本報告提供全球主要7個國家的急性骨髓性白血病 (AML) 調查分析、疾病的背景、危險因素和共生病症、全球趨勢、流行病學預測等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 危險因素和共生病症
    • 高齡化
    • 抽煙
    • 西班牙系、義大利系
    • 化療、放射治療
  • 全球趨勢
    • 發病率
    • 存活率、患病人數
    • 部分型和突然變異
    • 風險群
  • 預測手法
    • 利用之資訊來源
    • 預測的前提條件與手法
    • 未利用之資訊來源
  • AML的流行病學預測
    • AML和確診的患者數
    • AML和確診的患者數 (各年齡)
    • AML和確診的患者數 (性別)
    • AML和確診的患者數 (年齡標準化) 、等
  • 討論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER093-15

Acute myeloid leukemia (AML), also known as myelogenous leukemia, acute myelocytic leukemia, or acute nonlymphocytic leukemia, is a rare cancer that accounts for a disproportionally high number of cancer-related deaths. The disease is more common in the elderly, and is relatively more common in men than in women.

Acute promyelocytic leukemia (APL) and myelodysplastic syndromes (MDS)/therapy-related AML are two subtypes of AML that are especially unique in terms of disease etiology and prognosis, both of which will be discussed in detail in this report. Additionally, AML is associated with molecular gene mutations that are distinct from chromosomal structural abnormalities; of these, the best-studied is the FLT3 mutation (NCI, 2013). AML cases can also be stratified into three prognostic risk groups for treatment planning: favorable, intermediate, and adverse.

GlobalData epidemiologists estimate that the 7MM had 40,661 diagnosed incident cases of AML in 2014, nearly half of which occurred in the US. In the next 10 years, the 7MM will experience an increase in disease burden at a rate of 2.03% per year, which will be driven by population increase; this will result in 48,918 diagnosed incident cases of AML in 2024. For 2014, the number of diagnosed prevalent cases of AML was nearly identical to the number of diagnosed incident cases, at 44,079 cases, thereby underlining the lethality and poor long-term survival of the disease. The development of more effective therapies, particularly for elderly patients, would improve survival and increase disease prevalence.

Scope

The Acute Myeloid Leukemia (AML) EpiCast Report provides an overview of the risk factors and global trends of AML in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of the following segmentations in adults ages 20 years and older across the 7MM -

  • Diagnosed incident cases of AML, segmented by sex and 10-year age groups
  • Five-year diagnosed prevalent cases of AML, segmented by ages 20-59 years and ages 60 years and older
  • Diagnosed incident and five-year diagnosed prevalent cases of APL and MDS/therapy-related AML, segmented by ages 20-59 years and ages 60 years and older
  • Diagnosed incident cases of AML that have mutations in the FLT3 gene
  • Diagnosed incident cases of AML classified into favorable, intermediate, and adverse risk groups
  • The AML epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The AML EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global AML market.
  • Quantify patient populations in the global AML market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AML therapeutics in each of the markets covered.
  • Identify the percentage of AML cases by age, subtype, and risk group.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
    • 3.2.1. Increased age is associated with increased risk and worsened prognosis
    • 3.2.2. Smoking increases the risk of M2 AML
    • 3.2.3. APL is relatively common among Spanish and Italian origins
    • 3.2.4. Chemotherapy and radiation therapy increases the risk of AML
    • 3.2.5. Benzene increases risk of AML
  • 3.3. Global Trends
    • 3.3.1. Incidence
    • 3.3.2. Survival and Prevalence
    • 3.3.3. Subtypes and Mutations
    • 3.3.4. Risk Groups
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Forecast Assumptions and Methods
    • 3.4.3. Sources not Used
  • 3.5. Epidemiological Forecast for Acute Myeloid Leukemia (2014-2024)
    • 3.5.1. Adjusted Diagnosed Incident Cases of AML
    • 3.5.2. Adjusted Diagnosed Incident Cases of AML by Age
    • 3.5.3. Adjusted Diagnosed Incident Cases of AML by Sex
    • 3.5.4. Age-Standardized Incidence of AML
    • 3.5.5. APL and MDS/Therapy Related AML
    • 3.5.6. APL and MDS/Therapy Related AML by Age
    • 3.5.7. Diagnosed Incident Cases of AML with FLT3 Mutations
    • 3.5.8. Diagnosed Incident Cases of AML by Risk Group Classifications
    • 3.5.9. Five-Year Diagnosed Prevalent Cases of AML
    • 3.5.10. Five-Year Diagnosed Prevalent Cases of AML by Age
    • 3.5.11. Five-Year Diagnosed Prevalent Cases of APL and MDS/Therapy-Related AML
    • 3.5.12. Five-Year Diagnosed Prevalent Cases of APL and MDS/Therapy-Related AML by Age
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors for AML in Adults
  • Table 2: Incidence of AML per 100,000 Population in Japan, 1993-2002, All Ages
  • Table 3: Estimated Frequencies of Cytogenetic Abnormalities in AML
  • Table 4: Risk Group Classification Guidelines
  • Table 5: 7MM, Sources of AML Diagnosed Incidence
  • Table 6: 7MM, Adjusted Diagnosed Incident Cases of AML, Both Sexes, Ages ≥20 Years, N, Selected Years, 2014-2024
  • Table 7: 7MM, Adjusted Diagnosed Incident Cases of AML by Age, Both Sexes, N (Row %), 2014
  • Table 8: 7MM, Adjusted Diagnosed Incident Cases of AML by Sex, N (Row %), 2014
  • Table 9: 7MM, Diagnosed Incident Cases of APL, Both Sexes, Ages ≥20 Years, N, Selected Years, 2014-2024
  • Table 10: 7MM, Diagnosed Incident Cases of MDS/Therapy-related AML, Both Sexes, Ages ≥20 Years, N, Selected Years, 2014-2024
  • Table 11: 7MM, Diagnosed Incident Cases of AML Subtypes by Age, Both Sexes, N (Row % in Each Subtype), 2014
  • Table 12: 7MM, Diagnosed Incident Cases of AML with FLT3 Mutations, Both Sexes, Ages ≥20 Years, N, Selected Years 2014-2024
  • Table 13: 7MM, Diagnosed Incident Cases of AML by Risk Group Classification, Both Sexes, Ages ≥20 Years, N (Row %), 2014
  • Table 14: US, Risk Group Classification of AML Incident Cases by Age, Both Sexes, N (Row %), 2014
  • Table 15: 7MM, Five-Year Diagnosed Prevalent Cases of AML, Both Sexes, Ages ≥20 Years, N, Selected Years, 2014-2024
  • Table 16: 7MM, Five-Year Diagnosed Prevalent Cases of AML by Age, Both Sexes, N (Row %), 2014
  • Table 17: 7MM, Five-Year Diagnosed Prevalent Cases of APL, Both Sexes, Ages ≥20 Years, N, Selected Years, 2014-2024
  • Table 18: 7MM, Five-Year Diagnosed Prevalent Cases of MDS/Therapy-Related AML, Both Sexes, Ages ≥20 Years, N, Selected Years, 2014-2024
  • Table 19: 7MM, Five-Year Diagnosed Prevalent Cases of AML Subtypes by Age, Both Sexes, N (Row %), 2014

List of Figures

  • Figure 1: 7MM, Adjusted Diagnosed Incident Cases of AML, Both Sexes, Ages ≥20 Years, N, 2014-2024
  • Figure 2: 7MM, Adjusted Diagnosed Incident Cases of AML by Age, Both Sexes, Ages ≥20 Years, N, 2014
  • Figure 3: 7MM, Adjusted Diagnosed Incident Cases of AML by Sex, Ages ≥20 Years, N, 2014
  • Figure 4: 7MM, Age-Standardized Adjusted Diagnosed Incidence of AML, Ages ≥20 Years, 2014
  • Figure 5: 7MM, Diagnosed Incident Cases of APL, and MDS/Therapy-Related AML, Both Sexes, Ages ≥20 Years, N, 2014 and 2024
  • Figure 6: 7MM, Diagnosed Incident Cases of AML Subtypes by Age, Both Sexes, N, 2014
  • Figure 7: 7MM, Diagnosed Incident Cases of AML by Risk Group Classification, Both Sexes, Ages ≥20 Years, N, 2014
  • Figure 8: US, Risk Group Classification of AML Incident Cases by Age, Both Sexes, N, 2014
  • Figure 9: 7MM, Five-Year Diagnosed Prevalent Cases of AML, Both Sexes, Ages ≥20 Years, N, 2014-2024
Back to Top